Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Research & Development (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Research & Development for 4 consecutive years, with $54.5 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 10.51% to $54.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $172.2 million through Dec 2025, up 14.63% year-over-year, with the annual reading at $172.2 million for FY2025, 14.63% up from the prior year.
  • Research & Development for Q4 2025 was $54.5 million at Centessa Pharmaceuticals, up from $41.6 million in the prior quarter.
  • The five-year high for Research & Development was $60.9 million in Q4 2024, with the low at $22.7 million in Q1 2024.
  • Average Research & Development over 4 years is $37.6 million, with a median of $33.8 million recorded in 2023.
  • The sharpest move saw Research & Development tumbled 37.24% in 2023, then skyrocketed 104.85% in 2024.
  • Over 4 years, Research & Development stood at $27.8 million in 2022, then grew by 6.76% to $29.7 million in 2023, then skyrocketed by 104.85% to $60.9 million in 2024, then dropped by 10.51% to $54.5 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $54.5 million, $41.6 million, and $42.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.